Neurona Therapeutics
South San Francisco, US · 21 known investors
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter> <parameter name="founders">[]
Founders & leadership
CN
Cory NicholasFounder
JS
James StutzExecutive
AK
Arnold KriegsteinNamed on SEC filing
Board
PS
TK
Tim KutzkeyBoard director
RK
Ray KelleherBoard director
LG
Leo GuthartBoard director
DG
David GoeddelBoard director
BM
Brad MargusBoard director
EW
Erica WhittakerBoard director
SH
Stephen HauserBoard director
Investors · 21
Berkeley FrontierBerkeley
Iaso VenturesCambridge
The Column GroupSan Francisco · $30M
Ysios CapitalBarcelona · $5.4M – $21.6M
AlexandriareportedPasadena
Fidelity InvestmentsreportedBoston
LYFE CapitalreportedMenlo Park
Soleus CapitalreportedGreenwich
Spur Capital PartnersreportedBoston
SymBiosisreportedBentonville
UCB VenturesreportedBrussels
Viking Global InvestorsreportedStamford
Willett AdvisorsreportedNew York
YK BioventuresreportedBurlingame
Also in the syndicate · 7
Cormorant Asset ManagementEuclidean CapitalPassaic Capital ManagementSchroders CapitalSphera Biotech Master Fund LPUC InvestmentsYsios Capital Partners
Reported raises · per SEC filings
Form D private placements$347.5M disclosed across 6 rounds · 2014–2025
▶$101.7MraisedApr 2025 · 46 investors · BiotechnologyRule 506(b)
▶$101.7MraisedApr 2025 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter SvennilsonDirector
- Tim KutzkeyDirector
- Brad MargusDirector
- Cory NicholasExecutive Officer, Director, Promoter
- James StutzExecutive Officer
- Ray KelleherDirector
- Erica WhittakerDirector
- Leo GuthartDirector
- Offering amount
- $101.7M
- Amount sold
- $101.7M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120MraisedFeb 2024 · 35 investors · BiotechnologyRule 506(b)
▶$120MraisedFeb 2024 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ray KelleherDirector
- Erica WhitakerDirector
- Brad MargusDirector
- Tim KutzkeyDirector
- Robert TjianDirector
- Leo GuthartDirector
- Cory NicholasExecutive Officer, Director, Promoter
- James StutzExecutive Officer
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$72MraisedDec 2022 · 21 investors · BiotechnologyRule 506(b)
▶$72MraisedDec 2022 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold KriegsteinDirector
- Leo GuthartDirector
- Tim KutzkeyDirector
- Stephen HauserDirector
- Robert TjianDirector
- Erica WhittakerDirector
- Cory NicholasExecutive Officer, Director
- Brad MargusDirector
- Offering amount
- $91.6M
- Amount sold
- $72M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedNov 2019 · 9 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leo GuthartDirector
- Stephen HauserDirector
- Robert TjianDirector
- Arnold KriegsteinDirector
- Cory NicholasExecutive Officer, Director
- Tim KutzkeyExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $15M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2018 · 6 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leo GuthartDirector
- Robert TijanDirector
- Stephen HauserDirector
- Tim KutzkeyExecutive Officer, Director
- Arnold R. KriegsteinDirector
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$28.7MraisedDec 2016 · 13 investors · BiotechnologyRule 506(b)
▶$28.7MraisedDec 2016 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold KriegsteinDirector
- Stephen HauserDirector
- Tim KutzkeyExecutive Officer, Director
- David GoeddelDirector
- Leo GuthartDirector
- Offering amount
- $30.3M
- Amount sold
- $28.7M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neurona Therapeutics do?
- Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter> <parameter name="founders">[]
- Who founded Neurona Therapeutics?
- Neurona Therapeutics was founded by Cory Nicholas.
- Who are Neurona Therapeutics's investors?
- Neurona Therapeutics's investors include Berkeley Frontier, Iaso Ventures, The Column Group, Ysios Capital, Alexandria, Fidelity Investments, LYFE Capital, Soleus Capital and 6 more.
- How much funding has Neurona Therapeutics raised?
- Neurona Therapeutics has disclosed $347.5M raised across 6 rounds.
- Where is Neurona Therapeutics headquartered?
- Neurona Therapeutics is headquartered in South San Francisco, US.